Coffee and tea consumption, genotype-basedCYP1A2andNAT2activity and colorectal cancer risk-Results from the EPIC cohort study

Dec 10, 2013International journal of cancer

Coffee and tea drinking, genetic differences in caffeine processing, and colorectal cancer risk

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Data from 477,071 participants indicated that coffee and tea consumption is not likely to be associated with colorectal cancer (CRC).

After 11.6 years of follow-up, 4,234 participants developed CRC.
Total coffee consumption was not linked to CRC risk (hazard ratio 1.06).
Caffeinated coffee and decaffeinated coffee showed no significant association with CRC risk (hazard ratios 1.10 and 0.96, respectively).
Tea consumption also did not demonstrate a significant relationship with CRC risk (hazard ratio 0.97).
Caffeine metabolism, as indicated by CYP1A2 and NAT2 genotypes, did not modify the association between coffee and tea consumption and CRC risk.

AI simplified

Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.7 ± 8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC.

Full Text

Full text is available at the source.

View full text ↗

Coffee and tea consumption, genotype-basedCYP1A2andNAT2activity and colorectal cancer risk-Results from the EPIC cohort study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief